ERBB2 and breast cancer: The reasons were that neoadjuvant therapy could bring alteration of pathological profiles to BC, including hormone receptor status, HER‐2 status, and Ki‐67 index, which caused the change in molecular subtypes and would further influence patients' long‐term prognosis.38, 39, 40